Broad-spectrum antiviral activity and mechanism of antiviral action of the fluoroquinolone derivative K-12

Antiviral Chemistry and Chemotherapy

Volumn 9, Issue 5, 1998, Pages 403-411

  Witvrouw, M ^a   Daelemans, D ^a   Pannecouque, C ^a   Neyts, J ^a   Andrei, G ^a   Snoeck, R ^a   Vandamme, A M ^a   Balzarini, J ^a   Desmyter, J ^a   Baba, M ^b   De Clercq, E ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Herpesviruses; Human immunodeficiency virus; K 12; Quinolones; Transactivation

Indexed keywords

8 DIFLUOROMETHOXY 1 ETHYL 6 FLUORO 1,4 DIHYDRO 7 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL] 4 OXO 3 QUINOLINECARBOXYLIC ACID; ANTIVIRUS AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; COXSACKIE VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES VIRUS SAIMIRI; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; MOLONEY MURINE SARCOMA ONCOVIRUS; MONONUCLEAR CELL; NONHUMAN; PARAINFLUENZA VIRUS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SIMIAN IMMUNODEFICIENCY VIRUS; SINDBIS VIRUS; TOROVIRUS; VACCINIA VIRUS; VARICELLA ZOSTER VIRUS; VESICULAR STOMATITIS VIRUS; VIRUS INHIBITION; VIRUS TRANSCRIPTION;

EID: 0031710730     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029800900504     Document Type: Article

References (58)

1. Andrei G & De Clercq E (1990) Inhibitory effect of selected antiviral compounds on arenavirus replication in vitro. Antiviral Research 14:287-300.
2. Andriole VT (editor) (1988) The Quinolones. London: Academic Press.
3. Baba M, Schols D, Pauwels R, Nakashima H & De Clercq E (1990) Sulfated polysaccharides as potent inhibitors of HIV-induced syncytium formation: a new strategy toward AIDS chemotherapy. Journal of Acquired Immune Deficiency Syndromes 3:493-499.
4. Baba M, Okamoto M, Makino M, Kimura Y, Sakaguchi T & OkamotoT (1997) Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrobial Agents and Chemotherapy 41:1250-1255.
5. Balzarini J, Naesens L, Herdewijn P, Rosenberg I, Holy A, Pauwels R, Baba M, Johns DG & De Clercq E (1989) Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proceedings of the National Academy of Sciences, USA 86:332-336.
6. Balzarini J, Karlsson A, Pérez-Pérez M-J, Camarasa M-J & De Clercq E (1993) Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Virology 196:576-585.
7. Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vézinet-Brun F, Rouzioux C, Rozenbaum W & Montagnier L (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for AIDS. Science 220:868-871.
8. Bengal E & Aloni Y (1991) Transcriptional elongation by purified RNA polymerase II is blocked at the trans-activation-responsive region of human immunodeficiency virus type 1 in vitro. Journal of Virology 65:4910-4918.
9. Cherepanov P, Esté JA, Rando RF, Ojwang JO, Reekmans G, Steinfeld R, David G, De Clercq E & Debyser Z (1997) Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1. Molecular Pharmacology 52:771-780.
10. Cruciani M & Bassetti D (1994) The fluoroquinolones as treatment for infections caused by Gram-positive bacteria. Journal of Antimicrobial Chemotherapy 33:403-417.
11. Daelemans D, Esté JA, Witvrouw M, Pannecouque C, Jonckheere H, Aquaro S, Perno C-F, De Clercq E & Vandamme A-M (1997) S-adenosylhomocysteine hydrolase inhibitors interfere with the replication of human immunodeficiency virus type 1 through inhibition of the LTR transactivation. Molecular Pharmacology 52:1157-1163.
12. Daniel MD, Letvin NL, Sehgal PK, Hunsmann G, Schmidt DK, King NW & Desrosiers RC (1987) Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus. Journal of General Virology 68:3183-3189.
13. De Clercq E & Merigan TC (1971) Moloney sarcoma virus-induced tumors in mice: inhibition or stimulation by (poly rI).(poly rC). Proceedings of the Society for Experimental Biology and Medicine 137:590-593.
14. De Clercq E, Luczak M, Reepmeyer JC, Kirk KL & Cohen LA (1975) Fluoroimidazoles as antiviral agents and inhibitors of polynucleotide biosynthesis. Life Sciences 17:187-194.
15. De Clercq E, Descamps J, Verhelst G, Walker RT, Jones AS, Torrence PF & Shugar D (1980) Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. Journal of Infectious Diseases 141:563-574.
16. De Clercq E, Yamamoto N, Pauwels R, Baba M, Schols D, Nakashima H, Balzarini J, Debyser Z, Murrer BA, Schwartz D, Thornton D, Bridger G, Fricker S, Henson G, Abrams M & Picker D (1992) Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proceedings of the National Academy of Sciences, USA 89:5286-5290.
17. Dingwall C, Ernberg I, Gait MJ, Green SM, Heaphy S, Karn J, Lowe AD, Singh M, Skinner MA & Valerio R (1989) Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNA in vitro. Proceedings of the National Academy of Sciences, USA 86:6925-6929.
18. Felber BK, Drysdale CM & Pavlakis GN (1990) Feedback regulation of human immunodeficiency virus type 1 expression by the Rev protein. Journal of Virology 64:3734-3741.
19. Foley GE, Lazarus H, Farber S, Uzman BG, Boone BA & McCarthy RE (1965) Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 18:522-529.
20. Gatignol A, Kumar A, Rabson A & Jeang KT (1989) Identification of cellular proteins that bind to the human immunodeficiency virus type 1 trans-activation-responsive TAR element RNA. Proceedings of the National Academy of Sciences, USA 86:7828-7832.
21. Gatignol A, Buckler-White A, Berkhout B & Jeang KT (1991) Characterization of a human TAR RNA-binding protein that activates the HIV-LTR. Science 251:1597-1600.
22. Gaynor R, Soultanakis E, Kuwabara M, Garcia J & Sigman DS (1989) Specific binding of a HeLa cell nuclear protein to RNA sequences in the human immunodeficiency virus trans-activating region. Proceedings of the National Academy of Sciences, USA 86:4858-4862.
23. Gazdar AF, Carney DN, Bunn PA, Russell EK, Jaffe ES, Schechter GP & Guccion JG (1980) Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood 55:409-417.
24. Hamy F, Felder ER, Heizmann G, Lazdins J, Aboul-Ela F, Varani G, Karn J & Klimkait T (1997) An inhibitor of theTat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proceedings of the National Academy of Sciences, USA 94:3548-3553.
25. Hsu M-C, Schutt D, Holly M, Slice LW, Sherman MI, Richman DD, Potash MJ & Volsky DJ (1991) Inhibition of HIV replication in acute and chronic infections in vitro by a tat antagonist. Science 254:1799-1802.
26. Hsu M-C, Dhingra U, Earley JV, Holly M, Keith D, Nalin CM, Richou AR, Schutt AD, Tam SY, Potash MJ, Volsky DJ & Richman DD (1993) Inhibition of type 1 human immunodeficiency virus replication by a Tat antagonist to which the virus remains sensitive after prolonged exposure in vitro. Proceedings of the National Academy of Sciences, USA 90:6495-6499.
27. Kamine J, Subramanian T & Chinnadurai G (1991) Sp1-dependent activation of a synthetic promoter by human immunodeficiency virus type 1 Tat protein. Proceedings of the National Academy of Sciences, USA 88:8510-8514.
28. Kawana F, Shigeta S, Hosoya M, Suzuki H & De Clercq E (1987) Inhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitro. Antimicrobial Agents and Chemotherapy 31:1225-1230.
29. Keen NJ, Gait MJ & Karn J (1996) Human immunodeficiency virus type 1 Tat is an integral component of the activated transcription-elongation complex. Proceedings of the National Academy of Sciences, USA 93:2505-2510.
30. Kessler M & Mathews MB (1992) Tat transactivation of the human immunodeficiency virus type 1 promoter is influenced by basal promoter activity and the simian virus 40 origin of DNA replication. Proceedings of the National Academy of Sciences, USA 88:10018-10022.
31. Larder BA & Kemp SD (1989) Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246:1155-1158.
32. Maio JJ & Brown FL (1988) Regulation of expression driven by human immunodeficiency virus type 1 and human T-cell leukemia virus type I long terminal repeats in pluripotential human embryonic cells. Journal of Virology 62:1398-1407.
33. McGregor GR & Caskey CT (1989) Construction of plasmids that express E. coli beta-galactosidase in mammalian cells. Nucleic Acids Research 17:2365.
34. Michnc WF, Schroeder JD, Bailey TR, Young DC, Hughes JV & Dutko FJ (1993) Keto/enol epoxy steroids: a new structural class of HIV-1 Tat inhibitors. Journal of Medicinal Chemistry 36:2701-2702.
35. Miyoshi I, Taguchi H, Kobonishi I, Yoshimoto S, Ohtsuki Y, Shiraishi Y & Akagi T (1982) Type C virus-producing cell lines derived from adult T cell leukemia. Gann Monographs 28:219-228.
36. Nelbock P, Dillon PJ, Perkins A & Rosen CA (1990) A cDNA for a protein that interacts with the human immunodeficiency virus tat trans-activator. Science 248:1650-1653.
37. Neyts J & De Clercq E (1997) Antiviral drug susceptibility of human herpesvirus 8. Antimicrobial Agents and Chemotherapy 41:2754-2756.
38. Pauwels R, De Clercq E, Desmyter J, Balzarini J, Goubau P, Herdewijn P, Vanderhaeghe H & Vandeputte M (1987) Sensitive and rapid assay on MT-4 cells for the detection of antiviral compounds against the AIDS virus. Journal of Virological Methods 16:171-185.
39. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J & De Clercq E (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. Journal of Virological Methods 20:309-321.
40. Pauwels R, Andries K, Debyser Z, Kukla MJ, Schols D, Breslin HJ, Woestenborghs R, Desmyter J, Janssen MA, De Clercq E & Janssen PA (1994) New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynucleoside analogs. Antimicrobial Agents and Chemotherapy 38:2863-2870.
41. Perelson AS, Neumann AU, Markowitz M, Leonard JM & Ho DD (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
42. Popovic M, Sarngadharan MG, Read E & Gallo RC (1984) Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497-500.
43. Reed LJ & Muench H (1938) A simple method of estimating fifty percent endpoints. American Journal of Hygiene 27:493-497.
44. Rey MA, Krust B, Laurent AG, Guétard D, Montagnier L & Hovanessian AG (1989) Characterization of an HIV-2-related virus with a smaller sized extracellular envelope glycoprotein. Virology 173:258-267.
45. Salahuddin SZ, Markham PD, Wong-Staal F, Franchini G, Kalyanaraman VS & Gallo RC (1983) Restricted expression of human T-cell leukemia-lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. Virology 129:51-64.
46. Sambrook J, Fritsch EF & Maniatis T (1989) Expression of cloned genes in cultured mammalian cells. In Molecular Cloning: A Laboratory Manual, 2nd edn. Cold Spring Harbor: Cold Spring Harbor Laboratory Press.
47. Schmit J-C, Ruiz L, Clotet B, Raventos A, Tor J, Leonard J, Desmyter J, De Clercq E & Vandamme A-M (1996) Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 10:995-999.
48. + cells. Journal of Acquired Immune Deficiency Syndromes 2:10-15.
49. Schols D, Baba M, Pauwels R, Desmyter J & De Clercq E (1989b) Specific interaction of aurintricarboxylic acid with the human immunodeficiency/CD4 cell receptor. Proceedings of the National Academy of Sciences, USA 86:3322-3326.
50. Sherman PA & Fyfe JA (1990) Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity. Proceedings of the National Academy of Sciences, USA 87:5119-5123.
51. Shibuya H, Irie K, Ninomiya-Tsuji J, Goebl M, Taniguchi T & Matsumoto K (1992) New human gene encoding a positive modulator of HIV Tat-mediated transactivation. Nature 357:700-702.
52. Snoeck R, Andrei G & De Clercq E (1998) Current pharmacological approaches to the therapy of varicella-zoster virus infections: a guide to treatment. Drugs (in press).
53. Spire B, Sire J, Zachar V, Rey F, Barré-Sinoussi F, Galibert F, Hampe A & Chermann JC (1989) Nucleotide sequence of HIV1-NDK: a highly cytopathic strain of human immunodeficiency virus. Gene 81:275-284.
54. Vandamme A-M, Fransen K, Debaisieux L, Marissens D, Sprecher S, Vaira D, Vandenbroucke AT, Verhofstede C & the Belgian AIDS Reference Laboratories (1995) Standardisation of primers and an algorithm for HIV-1 diagnostic PCR evaluated in patients harbouring strains of diverse geographical origin. Journal of Virological Methods 51:305-316.
55. Vinckier F, Boogaerts M, De Clerck D & De Clercq E (1987) Chronic herpetic infection in an immunocompromised patient: report of a case. Journal of Oral and Maxillofacial Surgery 45:723-728.
56. Witvrouw M, Schols D, Andrei G, Snoeck R, Hosoya M, Pauwels R, Balzarini J & De Clercq E (1991) Antiviral activity of low-MW dextran sulfate (derived from dextran MW 1.000) compared to dextran sulfate samples of higher MW. Antiviral Chemistry & Chemotherapy 2:171-179.
57. Witvrouw M, Pauwels R, Vandamme A-M, Schols D, Reymen D, Yamamoto N, Desmyter J & De Clercq E (1992) Cell type-specific anti-human immunodeficiency virus type 1 activity of the transactivation inhibitor Ro5-3335. Antimicrobial Agents and Chemotherapy 36:2628-2633.
58. Wu F, Garcia J, Sigman D & Gaynor R (1991) Tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185. Genes and Development 5:2128-2140.